Renin-angiotensin-aldosterone-kinin system influences on diabetic vascular disease and cardiomyopathy

Mineral and Electrolyte Metabolism

Volumn 24, Issue 6, 1998, Pages 412-422

  Flack, John M ^a,c   Hamaty, Marwan ^a   Staffileno, Beth A ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

Diabetes; Renin angiotensin aldosterone kinin system; Vascular disease

Indexed keywords

ANGIOTENSIN; KININ; RENIN;

ARTERY INTIMA PROLIFERATION; CARDIOMYOPATHY; CELL PROLIFERATION; CONGESTIVE HEART FAILURE; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; GROWTH REGULATION; HORMONAL REGULATION; HUMAN; MUSCLE HYPERTROPHY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; STROKE; VASCULAR ENDOTHELIUM;

ALDOSTERONE; ANIMALS; CARDIOMYOPATHIES; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; HUMANS; KININS; RENIN-ANGIOTENSIN SYSTEM;

EID: 0032416313     PISSN: 03780392     EISSN: None     Source Type: Journal    
DOI: 10.1159/000057403     Document Type: Review

References (106)

1. Granger CB, Califf RM, Young S, Candela R, Samaha J, Worley S, Kereiakes DJ, Topol EJ: Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (JAMI) Study Group. J Am Coll Cardiol 1993;21:920-925.
2. Aronson D, Rayfield EJ, Chesebro JH: Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction. Ann Intern Med 1997;126:296-306.
3. Brazilay JI, Kronmal R, Bittner V, Eaker E, Evans C, Foster ED: Coronary artery disease and coronary artery bypass grafting in diabetic patients aged > 65 years (report from the Coronary Artery Surgery Study (CASS) Registry). Am J Cardiol 1994;74:334-339.
4. Bradley RF, Schonfeld A: Diminished pain in diabetic patients with acute myocardial infarction. Geriatrics 1962;17:322-326.
5. Kannel WB, McGce DL: Incidence and prognosis of unrecognized myocardial infarction: An update on the Framingham Study. N Engl J Med 1984;311:1142-1147.
6. Scheidt-Nave C, Barrett-Connor E, Wingard DL: Resting electrocardiographic abnormalities suggestive of asymptomatic ischemic heart disease associated with non-insulin-dependent diabetes mellitus in a defined population. Circulation 1990;81:899-906.
7. Nesto RW, Phillips RT, Kett KG, Hill T, Perper E, Young E, Leland OS: Angina and exertional myocardial ischemia in diabetic and nondiabetic patients: Assessment by thallium scintigraphy. Ann Intern Med 1988;108:170-175.
8. Abbott RD, Donahue RP, Kannel WB, Wilson PW: The impact of diabetes on survival following myocardial infarction in men vs. women. The Framingham Study. JAMA 1988;260:3456-3460.
9. Curb JD, Rodriguez BL, Burchfiel CM, Abbott RD, Chiu D, Yano K: Sudden death, impaired glucose tolerance, and diabetes in Japanese-American men. Circulation 1995;91:2591-2595.
10. Stegmayr B, Asplund K: Diabetes as a risk factor for stroke. A population perspective. Diabetologia 1995;38:1061-1068.
11. Barrett-Connor E, Khaw KT: Diabetes mellitus: An independent risk factor for stroke? Am J Epidemiol 1988;128:116-123.
12. Escobedo LG, Caspersen CJ: Risk factors for sudden coronary death in the United States. Epidemiology 1997;8:175-180.
13. Dineen SF, Gerstein HC: The association of microalbuminuria and mortalily in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 1997; 157:1413-1418.
14. Brancati FL, Whelton PK, Randall BL, Neaton JD, Stamler J, Klag MJ: Risk of end-stage renal disease in diabetes mellitus: A prospective cohort study of men screened for MRFIT. Multiple Risk Factor Intervention Trial. JAMA 1997;278:2069-2074.
15. Jaffe AS, Spandaro JJ, Schechtman K, Roberts R, Geltman EM, Sobel BE: Increased congestive heart failure after myocardial infarction of modest extent in patients with diabetes mellitus. Am Heart J 1984;108:31-37.
16. Barrett-Connor E, Wingard DL: Sex differential in ischemic heart disease mortality in diabetics: A prospective population-based study. Am J Epidemiol 1983;118:489-496.
17. Barrett-Connor E, Cohn BA, Wingard DL, Edelstein SL: Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than men? JAMA 1991;265:627-631.
18. Garcia MJ, McNamara PM, Gordon T, Kannel WB: Morbidity and mortality in diabetics in the Framingham population. Sixteen-year follow-up study. Diabetes Care 1990;13:631-654.
19. Lehto S, Pyrola K, Miettinen H, Ronnemaa T, Palomaki P, Tuomilehto J, Laakso M: Myocardial infarct size and mortality in patients with non-insulin-dependent diabetes mellitus. J Int Med 1994;236:291-297.
20. Abbud ZA, Shindler DM, Wilson AC, Kostis JB: Effect of diabetes mellitus on short-and long-term mortality rates of patients with acute myocardial infarction. A statewide study: Myocardial Infarction Data Acquisition System Study Group. Am Heart J 1995;130:51-58.
21. Sprafka JM, Burke GL, Folsom AR, McGovern PG, Hahn LP: Trends in prevalence of diabetes mellitus in patients with myocardial infarction and effect of diabetes on survival: The Minnesota Heart Survey. Diabetes Care 1991;14:537-543.
22. Orlander PR, Golf DC, Morrissey M, Ramsey DJ, Wear ML, Labarthe DR, Nichaman MA: The relation of diabetes to the severity of acute myocardial infarction and post-myocardial infarction survival in Mexican-Americans and non-Hispanic whites. The Corpus Christi Heart Project. Diabetes 1994;43:897-902.
23. Karlson BW, Herlitz J, Hjalmarson A: Prognosis of acute myocardial infarction in diabetic and non-diabetic patients. Diabetic Med 1993; 10:449-454.
24. Miettinen H, Lehto S, Saloman V, Mahonen M, Nimela M, Haffner SM, Pyrola K, Tuomilehto J: Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. Diabetes Care 1998;21:69-75.
25. Rytter L, Troelsen S, Beck-Nielsen H: Prevalence and mortality of acute myocardial infarction in diabetic patients. Diabetes Care 1985;8: 230-234.
26. Zarich SW, Arbuckle BE, Cohen LR, Roberts M, Nesto RW: Diastolic abnormalities in young asymptomatic diabetic patients assessed by pulsed Doppler echocardiography. J Am Coll Cardiol 1988;12:114-120.
27. Zoneraich S, Mollura JL: Diabetes and the heart: State of the art in the 1990s. Can J Cardiol 1993;9:293-299.
28. Messent JWC, Elliott TG, Hill RD, Jarrett RJ, Keen H, Viberti GC: Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: A twenty-three year follow-up study. Kidney Int 1992;41:836-839.
29. Dineen S, Gerstein H: Microalbuminuria and mortality in NIDDM: A systematic overview of the literature. Diabetes 1995:44:124A.
30. Morrish NJ, Stevens LK, Fuller JH, Jarrett RJ, Keen H: Risk factors for macrovascular disease in diabetes mellitus: The London follow-up to the WHO Multinational Study of Vascular Disease in Diabetics. Diabetologia 1991;34:590-594.
31. Walters DP, Gatling W, Mullee MA, Hill RD: The prevalence, detection, and epidemiological correlates of peripheral vascular disease: A comparison of diabetic and non-diabetic subjects in an English community. Diabetic Med 1992;9: 710-715.
32. Migdalis IN, Dimakopoulos N, Kourti A, Tolis A, Koutoulidis K, Samartzis M: The prevalence of peripheral vascular disease in type 2 diabetic-patients with and without proteinuria. Int Angiol 1994;13:229-232.
33. Henry P, Makowski S, Richard P, Beverelli F, Casanova S, Louali A, Boughalen K, Battaglia S, Guize L, Guermonprez JL: Increased incidence of moderate stenosis among patients with diabetes: Substrate for myocardial infarction? Am Heart J 1997;134:1037-1043.
34. Hasenfus G: Cardiac changes in diabetes. Exp Clin Endocrinol 1995;103:352-353.
35. Mustonen JN, Uusitupa MI, Laakso M, Vanninen E, Lansimies E, Kuikka JT, Pyorala K: Left ventricular systolic function in middle-aged diabetes mellitus patients. Am J Cardiol 1994; 73:1202-1208.
36. Mildenberger RR, Bar-Shlomo B, Druck MN, Jablonsky G, Morch JE, Hilton JD, Kenshole AB, Forbath N, McLaughlin PR: Clinically unrecognized ventricular dysfunction in young diabetic patients. J Am Coll Cardiol 1984;4:234-238.
37. Pitkanen OP, Nuutila P, Raitakari OT, Ronnemaa T, Koskinen PJ, Iida H, Lehtimaki TJ, Laine HK, Takala T, Viikari JS, Knuuti J: Coronary flow reserve is reduced in young men with IDDM. Diabetes 1998;47:248-254.
38. Strauer BE, Motz W, Vogt M, Schwartzkopff B: Impaired coronary flow reserve in NIDDM: A possible role for diabetic cardiopathy in humans. Diabetes 1997;46(suppl 2):119-124.
39. Dzau JV: Local expression and pathophysiological role of renin-angiotensin in the blood vessels and heart. Basic Res Cardiol 1993;88(suppl 1): 1-14.
40. Urata H, Nishmura H, Ganten D: Mechanisms of angiotensin II formation in humans. Eur Heart J 1995;16(suppl N):79-85.
41. Wolny A, Clozel JP, Rein J, Mory P, Voght P, Turino M, Kiowski W, Fischli W: Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res 1997;80:219-227.
42. Urata H, Nishimura H, Ganten D: Chymase-dependent angiotensin II forming system in humans. Am J Hypertens 1996;9:277-284.
43. Urata H, Boehm KD, Philip A, Kinoshita A, Gabrovsek J, Bumpus FM, Husain A: Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest 1993;91:1269-1281.
44. Johnson CI: Tissue angiotensin-converting enzyme in cardiac and vascular hypertrophy. Hypertension 1994;23:258-268.
45. 1 receptor subtype. Circ Res 1993;73:413-423.
46. Sadoshima JI, Izumo S: Autocrine secretion of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Contrib Nephrol. Basel, Karger. 1996, vol. 118, pp 214-221.
47. Kokkonen JO, Saarinen J, Kovanen PT: Regulation of local angiotensin II formation in the human heart in the presence of interstitial fluid. Inhibition of chymase by protease inhibitors of interstitial fluid and of angiotensin-converting enzyme by Ang(1-9) formed by heart carboxypeptidasae A-like activity. Circulation 1997;95: 1455-1463.
48. Nozavva Y, Miyake H, Haruno A, Yamada S, Uchida S, Ohkura T, Kimura R, Suzuki H, Hoshino T: Down-regulation of angiotensin II receptors in hypertrophied human myocardium. Clin Exp Pharmacol Physiol 1996;23:514-518.
49. Suzuki J, Matsubara H, Urkami M, Inada M: Rat angiotensin II (type 1A) receptor mRNA regulation and subtype expression in myocardial growth and hypertrophy. Circ Res 1993;73:439-447.
50. Booz GW, Baker KM: The role of the renin-angiotensin system in the pathophysiology of cardiac remodeling. Blood Press 1996;5(suppl 2):10-18.
51. Villereal FJ, Kim NN, Ungab GD, Printz MP, Dillman WH: Identification of functional angiotensin II receptors on rat cardiac fibroblasts. Circulation 1993;88:2849-2861.
52. Yamazaki T, Komuro I, Kudoh S, Zou Y, Shiojima I, Mizuno T, Takano H, Hiori Y, Ueki K, Tobe K, Kadwaki T, Nagai R, Yazaki Y: Angiotensin II partly mediates mechanical stress-induced cardiac hypertrophy. Circ Res 1995;77:258-265.
53. Yamazaki Komuro I, Shiojima I, Yazaki Y: The renin-angiotensin system and cardiac hypertrophy. Heart 1996;76(suppl 3):33-35.
54. Reynolds MV, Perryman MB: The role of genetic variants in angiotensin I converting enzyme, angiotensinogen and angiotensin II type-1 receptor in the pathophysiology of heart muscle disease. Eur Heart J 1995;16(suppl K): 23-30.
55. 1 in adult rat cardiac fibroblasts. J Mol Cell Cardiol 1995;27:2347-2357.
56. 1 receptor by transcriptional and posttranscriptional mechanisms: Evidence for homologous and heterologous regulation. Mol Parmacol 1995;48:601-609.
57. Okunishi H, Oka Y, Shiota N, Kawamoto T, Song K, Miyazaki M: Marked species difference in the vascular angiotensin II-forming pathways: Humans versus rodents. Jpn J Pharmacol 1993;62:207-210.
58. Shalitin N, Friedman M, Schlesinger H, Barhum Y, Levy MJ, Schafer W, Kessler-Icekson G: The effect of angiotensin II on myosin heavy chain expression in cultured myocardial cells. In Vitro Dev Biol Anim 1996;32:573-578.
59. 2 receptor subtypes in vascular trophic and phenotypic changes in response to stimulation with angiotensin II. Arterioscler Thromb Biol 1997;17:257-264.
60. Susic D, Nunez E, Frolich ED, Prakash O: Angiotensin II increases left ventricular mass without affecting myosin isoform mRNAs. Hypertension 1996;28:265-268.
61. Shiota N, Okunishi H, Fukamizu A, Sakonjo H, Kikomori M, Nishimura T, Nakagawa T, Murakami K, Miyazki M: Activation of two angiotensin-generating systems in the balloon-injured artery. FEBS Lett 1993;323:239-242.
62. 1 in the cellular growth response to angiotensin II. Hypertension 1993;21:1046-1050.
63. Naruse M, Wasada T, Naruse K, Yoshimoto T, Omori Y, Demura H: Pathophysiological significance of plasma total renin and prorenin in patients with diabetes mellitus. Endocr J 1995; 42:225-233.
64. Bryer-Ash M, Fraze EB, Luetscher JA: Plasma renin and prorenin (inactive renin) in diabetes mellitus: Effects of intravenous furosemide. J Clin Endocrinol Metab 1988;66:454-458.
65. Bell GM, Bernstein RK, Laragh JH, Atlas SA, James GD, Pecker MS, Sealey JE: Increased plasma atrial natriuretic factor and reduced plasma renin in patients with poorly controlled diabetes mellitus. Clin Sci 1989;77:177-182.
66. Lush DJ, King JA, Fray JCS: Pathophysiology of low renin syndromes: Sites of renal renin secretory impairment and prorenin overexpression. Kidney Int 1993;43:983-999.
67. Paulsen EP, Seip RL, Ayers CR, Crofty BY, Kaiser DL: Plasma renin activity and albumin excretion in teenage type I diabetic subjects. Hypertension 1989;13:781-789.
68. Hollenberg NK, Fisher NDL: Renal circulation and blockade of the renin-angiotensin system. Hypertension 1995;26:602-609.
69. Fisher NDL, Allan DR, Gaboury CL, Hollenberg NK: Intrarenal angiotensin II formation in humans: Evidence from renin inhibition. Hypertension 1995;25:935-939.
70. Christlieb AR: Diabetes and hypertensive and vascular diseases: Mechanisms and treatment. Am J Cardiol 1973;32:592-606.
71. Christlieb AR: Renin-angiotensin-aldosterone system in diabetes mellitus. Diabetes 1976; 25(suppl 2):820-825.
72. Everett AD, Scott J, Wilfong N, Marino B, Rosenkranz RP, Inagami T, Gomez RA: Renin and angiotensinogen expression during the evolution of diabetes. Hypertension 1992;19:70-78.
73. Luetscher JA, Kraemer FB, Wilson DM, Bryer-Ash M: Increased plasma inactive renin in diabetes mellitus: Marker of microvascular complications. N Engl J Med 1985;312:1412-1417.
74. Nitenberg A, Valensi P, Sachs R, Dali M, Aptecar E, Attali JR: Impairment of coronary vascular reserve and Ach-induced coronary vasodilation in diabetic patients with angiographically normal coronary arteries and normal left ventricular systolic function. Diabetes 1993;42: 1017-1025.
75. Mancini GB, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, Wargovich TJ, Mudra H, Lusher TF, Klibaner MI, Haber HE, Uprichard AC, Repine CJ, Pitt B: Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation 1996;94:258-265.
76. Sowers JR: Diabetes mellitus and cardiovascular disease in women. Arch Intern Med 1998; 158:617-621.
77. Hong MK, Romm PA, Reagan K, Green CE, Rackley CE: Effects of estrogen replacement therapy on serum lipid values and angiographically defined coronary artery disease in postmenopausal women. Am J Cardiol 1992;69: 176-178.
78. Mehta JL, Chen LY, Kone BC, Mehta P, Turner P: Identification of constitutive and inducible forms of nitric oxide synthase in human platelets. J Lab Clin Med 1995;25:370-377.
79. Lieberman EH, Gerhard MD, Uehata A, Walsh BW, Selwyn AP, Ganz P, Yeung AC, Creager MA: Estrogen improves endothelium-dependent, flow-mediated vasodilation in post-menopausal women. Ann Intern Med 1994;121: 936-941.
80. Cooper R, McFarlane-Anderson N, Bennet FI, Wilks R, Puras A, Tewsbuty D, Ward R, Forrester T: ACE, angiotensin and obesity: A potential pathway leading to hypertension. J Hum Hypertens 1997;11:107-111.
81. Zinner SH, Margolius HS, Rosner B, Keiser HR, Kass EH: Familial aggregation of urinary kallikrein concentration in childhood: Relation to blood pressure, race and urinary electrolytes. Am J Epidemiol 1976;104:124-132.
82. Sowers JR: Insulin and insulin-like growth factor in normal and pathological cardiovascular physiology. Hypertension 1997;29:691-699.
83. Bucala R, Tracey KJ, Cerami A: Advanced glycosylation products quench nitric oxide and mediate detective endothelium-dependent vasodilation in experimental diabetes. J Clin Invest 1991;87:432-438.
84. Sechi LA, Griffin CA, Schambelan M: The cardiac renin-angiotensin system in STZ-induced diabetes. Diabetes 1994;43:1180-1184.
85. Lorel BH: Cardiac renin-angiotensin system: Role in the development of pressure-overload hypertrophy. Can J Cardiol 1995;11(suppl F): 7-12.
86. Lee YA, Liang CS, Lee MA, Lindpainter K: Local stress, not systemic factors regulate gene expression of the cardiac renin-angiotensin system in vivo. A comprehensive study of all its components in the dog. Proc Natl Acad Sci USA 1996;93:11035-11040.
87. Brown L, Serina C: Angiotensin receptors in cardiovascular diseases. Clin Exp Pharmacol Physiol 1994;21:811-818.
88. Brown L, Wall D, Marchant C, Serina C: Tissue-specific changes in angiotensin II receptors in streptozotocin-diabetic rats. J Endocrinol 1997; 154:355-362.
89. 1 receptor gene regulation in cardiac myocytes and fibroblast. J Mol Cell Cardiol 1996;28:1727-1736.
90. Diet F, Pratt RE, Berry GJ, Momose N, Gibbons GH, Dzau VJ: Increased accumulation of tissue ACE in humans athersclerotic coronary artery disease. Circulation 1996;94:2756-2767.
91. Sugiyama F, Haraoka S, Watanabe T, Shiota N, Tanguchi K, Ueno Y, Tanimoto K, Murakami K, Fukamizu A, Yagami KI: Acceleration of atherosclerotic lesions in transgenic mice with hypertension by the activated renin-angiotensin system. Lab Invest 1997;76:835-842.
92. Takai S, Shiota N, Kobayashi S, Matsumura E, Miyazaki M: Induction of chymase that forms angiotensin II in the monkey atherosclerotic aorta. FEBS Lett 1997;412:86-90.
93. Sharpe N: The effects of ACE inhibition on progression of atherosclerosis. J Cardiovasc Pharmacol 1993;22(suppl 9):9-12.
94. Mancini JGB: Emerging concepts: Angiotensin-converting enzyme inhibition in coronary artery disease. Cardiovasc Drugs Ther 1996;10: 609-612.
95. Ohishi M, Ueda M, Rakugi H, Naruko T, Koima A, Okamura A, Higaki J, Ogihara T: Enhanced expression of angiotensin-converting enzyme is associated with progression of coronary atherosclerosis in humans. J Hypertens 1997;15:1295-1302.
96. Rosendorf C: The renin-angiotensin system and vascular hypertrophy. J Am Coll Cardiol 1996; 28:803-812.
97. Ridker PM: An epidemiologic assessment of thrombotic risk factors for cardiovascular disease. Curr Opin Lipidol 1992;3:285-290.
98. Luscher TF, Boulanger CM, Dohi Y, Zang Z: Endothelium-derived contracting factors. Hypertension 1992;19:117-130.
99. Pitt B: Therapy of left ventricular dysfunction: Implications from recent therapeutic trials and future directions for therapy. Schweiz Med Wochenschr 1993;123:342-348.
100. Zuanetti G, Latini R, Maggioni AP, Franzosi MG, Santoro L, Tognoni G for the GISS-3 Investigators: Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction. Circulation 1997; 96:4239-4245.
101. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998;338:645-652.
102. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, Strollo F: Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FA-CET) in patients with hypertension and NIDDM. Diabetes Care 1998;21:597-603.
103. Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT, Cushman WC, Grimm RH, LaRosa J, Whelton PK, Perry HM, Alderman MH, Ford CE, Oparil S, Francis C, Proschan M, Pressel S, Black HR, Hawkins CM: Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens 1996;9:342-360.
104. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, Camel G, Davis BR, Frost PH, Gonzalez N, Guthrie G, Oberman A, Rutan GH, Stamler J: Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk factor in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996; 276:1186-1892.
105. The Hypertension Detection and Follow-Up Program Cooperative Research Group: Mortality findings for stepped-care and referred-care participants in the hypertension detection and follow-up program, stratified by other risk factors. Prev Med 1985;14:312-314.
106. Zuanetti G, Latini R: Impact of pharmacological treatment on mortality after myocardial infarction in diabetic patients. J Diabetes Complications 1997;11:131-136.